NorthWest Biotherapeutics Inc (NWBO)

[Maverick0408]

MHRA approval won’t happen for another 6 months, but let’s touch bases on your share price predictions in 2 months! I’d say there will be no FDA BLA submission in Q2. The only application they will submit in Q2 will be MHRA.

No reason for big investor to pay 2-3 X of the share price for an OTC stock with the history of this management team coupled with the market volatility and tight financing we will be seeing in the coming months.

Again, 50 patients per month volume will not happen in 2023. Even if they set the price at $150k that won’t happen. But again, they won’t lower the price to under $200k as it sets bad business precedence and will make their life difficult extremely difficult with reimbursement negotiations in the future. It would be a bad business move!